Form 4/A for XLO Xilio Therapeutics, Inc.
Accepted 2021-11-03 00:00:00 ET · period of report 2021-10-26 · accession 0000899243-21-042710 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAI | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DMA | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DA | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
| DAI | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
| DMA | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | $0.00 | -12.36M | 0 | -100% | $0 |
| DMAI | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | $0.00 | -12.36M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-26 | C | A | 998,544 | — | 998,544 | I See footnote | — | — | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. (F2) Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. (F3) Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| 2 | Common | Common Stock | 2021-10-26 | C | A | 998,544 | — | 998,544 | D See footnote | — | — | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. (F2) Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. (F3) Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| 3 | Common | Common Stock | 2021-10-26 | C | A | 302,588 | — | 1,301,132 | D See footnote | — | — | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. (F2) Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. (F3) Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| 4 | Common | Common Stock | 2021-10-26 | C | A | 302,588 | — | 1,301,132 | I | — | — | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. (F2) Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. |
| 5 | Common | Common Stock | 2021-10-26 | P | A | 312,500 | $16.00 | 1,613,632 | D | — | — | (F4) This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. |
| 6 | Common | Common Stock | 2021-10-26 | P | A | 312,500 | $16.00 | 1,613,632 | I | — | — | (F4) This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. |
| 7 | Derivative | Series B Convertible Preferred Stock | 2021-10-26 | C | D | 9,486,166 | $0.00 | 0 | D See footnote | — · — to — | 998,544 Common Stock | (F3) Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |
| 8 | Derivative | Series C Convertible Preferred Stock | 2021-10-26 | C | D | 2,874,595 | $0.00 | 0 | I | — · — to — | 302,588 Common Stock | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |
| 9 | Derivative | Series C Convertible Preferred Stock | 2021-10-26 | C | D | 2,874,595 | $0.00 | 0 | D | — · — to — | 302,588 Common Stock | (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |
| 10 | Derivative | Series B Convertible Preferred Stock | 2021-10-26 | C | D | 9,486,166 | $0.00 | 0 | I See footnote | — · — to — | 998,544 Common Stock | (F3) Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. (F1) The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |